Close Menu

This article, originally published on July 12, has been updated from a previous version to include a statement from Cepheid.

Point-of-care diagnostic firm Abaxis has sued Cepheid, alleging that its PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes sample-prep patents owned by Abaxis, according to recently filed court documents.

In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.